Est. 2001·3,000+ placements · six offices · four regions

Company signals · Biotech & Pharma

Promomed Group

1 signal in the current window, with MitchelLake's leadership read on each.

Last updated

Market context: Backdrop: a 109 (Hot) Talent Market Index (up 7.3 on the month) with Asia activity rising (+2.7pts).

Promomed Group: 0 signals in the last 90 days — below the Biotech & Pharma median of 1 across 33 tracked companies.

Signals at Promomed Group

Geographic Expansion

Asia

Promomed Group (Russian pharmaceutical company) is expanding into Vietnam's pharmaceutical market with strategic partnerships. Founder Petr Bely met with Vietnam's Minister of Health to discuss long-term cooperation, technology transfer, and manufacturing operations targeting innovative drugs, biosimilars, and monoclonal antibodies

Leadership read: Promomed has moved from a bilateral MoU signed in September 2025 into active ministry-level operational discussions, a materially different posture. The September agreement was witnessed ceremony; this meeting produced Drug Administration of Vietnam tasking on regulatory procedures, a named second distribution partner (CPC1 alongside Vinapharm), and a ministerial instruction to develop a strategic framework. The company has now committed to a multi-entity, multi-product regulatory pathway in a market with its own procurement rules, local content expectations, and a newly enacted Pharmaceuticals Law, none of which were on its plate before the 2025 MoU closed. This is one of 12 geographic expansion signals we have tracked across sectors in the last 90 days, though the comparable set is thin on pharma-to-Southeast-Asia specifically. The broader pattern is consistent: companies pairing a government-level relationship with a named local distribution partner are accelerating from soft entry to operational commitment faster than prior cycles suggested. Vietnam's active solicitation of technology-transfer manufacturing, biosimilars and monoclonal antibodies in particular, is drawing producers who can offer both product and process, not just import volume. Companies reaching this stage of government-partnered pharma expansion in Southeast Asia face concentrated demand for regulatory affairs leadership fluent in ASEAN registration pathways, commercial operations capable of managing multi-distributor channel conflict, and technology-transfer program management with local manufacturing integration experience. That functional combination is structurally scarce in the Russia-Vietnam corridor specifically.

curated · 2026-05-13 · context →

MitchelLake in this thematic

More signals across Biotech & Pharma

Geographic Expansion · Asia

Gilead Sciences →

Gilead is reportedly turning to an executive from BeOne to support its China expansion, signalling a push into the Chinese market.

Geographic Expansion · Asia

Thermo Fisher Scientific →

Thermo Fisher Scientific's Manila Shared Services Centre is scaling rapidly from 100 to ~700 employees by 2026, positioning itself as a high-impact regional hub for Asia-Pacific operations with focus on digital transformation and strategic value creation beyond cost efficiency.

Partnership · Asia

Bora Pharmaceuticals →

Bora Pharmaceuticals signed partnership with Insilico Medicine for AI drug discovery. Company launched group-wide AI in Manufacturing program (BORA AIM) to improve process efficiency across sites.

Product Launch · Asia

Biogen →

Biogen's monoclonal antibody felzartamab received first global approval in China for second-line multiple myeloma treatment, in combination with lenalidomide and dexamethasone.

Product Launch · Asia

Celltrion →

Celltrion achieved record quarterly earnings (1.4 trillion won / $950M in sales, 451.8B won operating profit) driven by growing sales of newer biosimilar portfolio and improved manufacturing efficiency. YoY sales growth of 45% and operating profit growth of 86.3%.

Product Launch · Asia

Bristol Myers Squibb →

Bristol Myers Squibb launched Relopduo, a fixed-dose combination dermatology-cancer drug, in India. The drug received USFDA approval in 2022 and is now being commercialized in the Indian market.

Where Promomed Group's market lands in our work

Weekly briefing

Track companies like Promomed Group — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record

MitchelLake is a global executive search and advisory firm covering AI, innovation and expansion leadership for companies navigating transformation and change across industries, from startups and scale-ups to private-equity-backed and enterprise organisations. 3,000+ C-suite, specialist and board placements since 2001.

Data period
13 May 2026 – 13 May 2026 · 1 signals for this company
Publisher
MitchelLake

Last updated